Board summary
Key figures
67,260
Registered population
61.3% aged 18–64
19.1%
Aged 65+
ICB 19.0% · England 17.9%
3.6%
Ethnic minority (non-White)
1.1% Asian · England 9.6%
50.7%
In IMD quintile 1
ICB 31.9% · England 21.0%
~35,431
Core20 residents (est.)
Resident basis; registered basis ~34,109 · see page 3
12,139
Hypertension register
+5.31% in 3 yrs · England +5.60%
682
SMI register
52.1% of Halton (LAD)'s
2,421
COPD register
Reviews +8.49% in 3 yrs
Forecast to 2030
13,582
Hypertension patients, 2030
+1,443 on today
70.5%
QRISK ≥20% on statins, 2030
+2.78pp over 3 yrs
5.2%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma review coverage trails England across large register.
Across 5,342 asthma patients (8.3% prevalence vs England 6.6%), 64.0% had an annual review (England 65.7%), leaving about 1,900 unreviewed, which may reflect recall.
Hypertension target growth and statin reach lag England.
Three-year hypertension treatment to target rose +0.6% (England +3.6%) and diabetes primary-prevention statins reached 66.7% (England 73.2%), which could reflect review or escalation delays.
Heart failure and mental health checks outpace England.
Heart failure reviews rose +26.7% over three years to 82.8% (England 78.5%), while mental health BMI recording rose +12.1 pp (England +5.1 pp).
Population, age and ethnicity
An older age profile of 19.1% pairs with substantial borough inclusion caseloads
Across 67,260 registered patients, 19.1% (12,839) are aged 65+, exceeding Halton (LAD) (17.5%), matching NHS Cheshire and Merseyside ICB (19.0%), and above England (17.9%). Projected list growth to 2030 is 0.9% against 1.0% in Halton (LAD), 2.3% in the ICB, and 2.3% in England (unverified methodology). Census usual-resident estimates indicate 96.4% White ethnicity compared to 96.5% in Halton (LAD), 93.0% in the ICB, and 81.1% in England, reflecting a 3.6% ethnic minority population.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Halton (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Halton LA) | 2,194 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 83.4% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 55.4% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Halton LA) | 1,120 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Halton LA) | 21.7 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 areas house 50.7% of registered patients, varying widely across member practices
Across RUNCORN PCN, 50.7% of registered patients live in Core20 areas, exceeding Halton (LAD) (44.7%), the ICB (31.9%) and England (21.0%), with an average IMD decile of 3.7 (England 5.5). Concentration spans 42.8 pp, from 27.2% at Tower House Practice to 70.0% at Weaver Vale Practice. Castlefields Health Centre carries the highest volume with 10,267 estimated Core20 patients (65.8% share). Resident Core20 estimates (35,431) and registered patient lists use different bases. Targeting interventions purely by practice deprivation rate risks leaving the largest absolute Core20 cohort underserved.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
682
SMI register
1.00% recorded prevalence
489
Learning disability register
0.71% recorded prevalence
9
Care homes, 293 beds
In the PCN catchment
11.3%
Provide unpaid care
Halton (LAD), Census 2021
The PCN records 682 patients with severe mental illness (52.1% of the borough register) and 489 with learning disabilities (52% of the borough register; 0.7% prevalence versus Halton (LAD) 0.7%, the ICB 0.6%, and England 0.6%), alongside 9 catchment care homes with 293 beds. Holding over half the borough's recorded caseload across both registers represents a substantial primary care workload to sustain.
Severe mental illness: physical health checks
SMI prevalence is 1.0% (England 1.0%). For physical health checks, blood pressure review reaches 82.8% (England 83.4%), BMI recording reaches 82.9% (England 82.1%), and alcohol status recording reaches 79.8% (England 81.8%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
12,139
Hypertension register
+5.31%
Register growth, 3 yrs
Halton (LAD) +6.68% · England +5.60%
+0.51pp
BP control, under 80
≤140/90 · +1.08pp aged 80+
+1,443
More patients by 2030
Forecast 13,582 (19.66%)
Hypertension case-finding and control
Runcorn PCN records 12,139 patients on its hypertension register, representing 17.7% prevalence, matching Halton (LAD) (17.7%) and above England (15.2%). While blood pressure recording reaches 89.1% (England 90.0%) and treatment to target reaches 70.0% (England 70.3%), three-year progress trailed England in recording (+0.9% versus +3.6%) and treatment to threshold (+0.6% versus +3.6%). Trailing three-year progress across 12,139 hypertensive patients suggests routine blood pressure monitoring and titration could be prioritised to prevent plateauing control.
Lipids and statins
Statin treatment for diabetes primary prevention sits at 66.7%, trailing Halton (LAD) (68.5%), the ICB (72.4%) and England (73.2%), alongside 2,412 adult lipid-modifying items prescribed per 1,000 (England 4,100). Lower primary-prevention statin coverage than in England suggests an under-served diabetic cohort where proactive cardiovascular reviews could be prioritised.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 130,463 | £1.80 | £1.71 | £1.86 | £234,833 |
| Cardiovascular (all), 2025 | 187,006 | £4.25 | £4.37 | £3.33 | £794,776 |
In 2026, the PCN prescribed 130,463 lipid-modifying items at £1.80 per item (spend £234,833), against £1.87 in Halton (LAD), £1.71 in the ICB and £1.86 in England. This was £7,828 less than at England's unit cost, but £11,742 more than at NHS Cheshire and Merseyside ICB's unit cost.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+6.73%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+1.28%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 8.3% (5,342 patients; England 6.6%) and management prescribing is 2,628 items per 1,000 aged 5-19 (England 1,488). Annual reviews reach 64.0% (England 65.7%), leaving about 1,900 patients unreviewed. COPD prevalence is 3.5% (2,421 patients; England 1.9%) with reviews reaching 76.8% (England 76.4%). High youth prescribing alongside lower review coverage could reflect recall gaps to test by auditing practice call-recall lists.
Cancer register and children's immunisation
Cancer prevalence is 4.2% (2,875 patients; England 3.8%). In childhood immunisations, MMR dose 1 at age 5 reaches 96.2% (England 91.7%), but dose 2 drops 5 pp to 91.2% (England 82.8%), sitting below the 95.0% target by 3.8 pp. Pre-school 4-in-1 booster reaches 90.6%. This drop between doses could reflect recall timing to test by reviewing practice call-recall lists.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
Across NHS Cheshire and Merseyside ICB in 2022, 55.5% of cancers were diagnosed at stage 1 or 2 (7,482 of 13,490 known-stage cases), sitting 19.5 pp below the 75.0% national ambition by 2028, in line with England (55.3%). Staging was recorded for 72.8% of 18,522 registered cancers. Early-stage share increased 2.6 pp from 52.8% in 2013, requiring about 2,640 extra early diagnoses annually across the ICB to reach 75.0%. Runcorn PCN cancer prevalence reached 4.2% (2,875 patients), rising +10.8% over three years (England +9.0%), while breast screening coverage (+5.0%) trailed England (+8.4%). Staging reflects wider system diagnostics rather than PCN performance, but strengthening primary care screening uptake supports earlier referral.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional), North Cheshire and Mersey NHS Foundation Trust achieved 83.7% on the 62-day referral to treatment standard, 1.3 pp below the 85.0% standard, but exceeding NHS Cheshire and Merseyside Integrated Care Board (76.2%), Mersey and West Lancashire Teaching Hospitals NHS Trust (78.0%) and England (71.2%). The trust met the 28-day faster diagnosis standard at 80.2% (standard 75.0%) and 31-day combined standard at 98.2% (standard 96.0%). Patients waiting 6+ weeks were 0.0% for non-obstetric ultrasound and 0.5% for Magnetic Resonance Imaging. These provider metrics reflect acute system access rather than dedicated PCN performance.
| Pathways within standard (%) | North Cheshire and Mersey | Mersey and West Lancashire | Liverpool | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.21 | 72.39 | 75.47 | 77.25 | 79.32 |
| 31-day treatment (96%) | 98.17 | 95.46 | 90.51 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 83.67 | 77.96 | 73.26 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | North Cheshire and Mersey | Mersey and West Lancashire | Liverpool | England |
|---|---|---|---|---|
| MRI | 0.53 | 14.04 | 6.42 | 21.40 |
| CT | 2.32 | 13.08 | 0.71 | 9.92 |
| Echocardiography | 28.04 | 34.88 | 12.55 | 28.48 |
| Colonoscopy | 15.98 | 18.04 | 33.14 | 30.83 |
| Gastroscopy | 20.24 | 18.17 | 44.99 | 29.02 |
| All 15 DM01 tests | 6.34 | 21.17 | 11.50 | 23.14 |
| Community services activity | Halton residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 19,830 | 541,280 |
| Referrals | 3,185 | 97,150 |
| Patients with a contact | 6,225 | 146,240 |
Community services (residents of Halton), Jun 2026 (provisional). In the provisional Jun 2026 Community Services Dataset, 57.1% of community contacts for Halton borough residents were with adults aged 65 and over (11,325 of 19,830 total contacts). These data describe borough resident activity rather than PCN-level patient contacts, highlighting high community care volume among older people across the local authority.
Practice variation and patient experience
Practice variation and patient experience
In 2025/26, QOF clinical achievement was 88.2% at Murdishaw, while Grove House Practice achieved 100.0%. Across England, the clinical achievement comparator was 97.1%. For vaccination and immunisation, Murdishaw achieved 28.5%, whereas Grove House Practice achieved 81.3%, spanning a range of 52.8 pp. The England comparator for vaccination and immunisation was 55.2%.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Castlefields | 103 | 65.8 | 68.5% | 60.8% | 82.8% |
| Brookvale Practice | 114 | 68.2 | 59.9% | 76.2% | 78.9% |
| Grove House | 121 | 33.6 | 44.5% | 67.8% | 72.4% |
| Weaver Vale | 111 | 70.0 | 48.2% | 58.5% | 67.3% |
| Tower House | 109 | 27.2 | 45.3% | 72.7% | 65.5% |
| Murdishaw | 104 | 48.8 | 31.9% | 75.6% | 59.4% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Eight three-year measures trail England, while heart failure reviews rose +26.7%
Eight measures trail England over three years. Relative three-year gains lagged in breast screening (+5.0% versus +8.4% in England), hypertension treatment to threshold (+0.6% versus +3.6%), and blood pressure recording (+0.9% versus +3.6%). Conversely, heart failure reviews achieved a relative three-year gain of +26.7% (England +8.7%, reaching 82.8% current coverage), non-frail diabetes HbA1c control rose +10.3% (England +4.4%), and severe mental illness annual BMI recording expanded +12.1 pp (England +5.1 pp).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Breast screening (53-70)
Hypertension treated to target
Hypertension BP reading
BP control, under 80
COPD register
Heart failure reviews
BMI record (SMI)
Diabetes HbA1c control
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Halton (LAD) | Asset | PCN | Halton (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 9 (293 beds) | n/a | Schools (catchment) | 69 | n/a |
| Children's centres | 4 | 8 | Places of worship | 26 | 55 |
| Libraries | 1 | 2 | Primary schools (LA maintained) | 19 | 33 |
| Primary academies | 9 | 13 | Special schools | n/a | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Standardise annual asthma review recall
Annual asthma reviews reach 64.0% (England 65.7%) across 5,342 patients (8.3% prevalence versus England 6.6%), leaving about 1,900 unreviewed alongside 2,628 youth asthma items per 1,000 (England 1,488). For discussion, practices could run a single recall template pairing inhaler prescribing checks with flexible after-school or holiday review slots. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Structured hypertension and statin recall
Across 12,139 hypertension patients (17.7%, England 15.2%), three-year gains trailed England in BP recording (+0.9% versus +3.6%) and target treatment (+0.6% versus +3.6%), with diabetic statin coverage at 66.7% (England 73.2%). For discussion, pharmacist-led clinics could check overdue blood pressures, escalate antihypertensives and review statins for diabetic patients. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Pre-school MMR2 and booster recall
At age 5 (cohort 159), MMR coverage drops 5 pp from dose 1 (96.2%) to dose 2 (91.2%, 3.8 pp below the 95.0% target), with 4-in-1 booster coverage at 90.6%. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult care reviews (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Dual track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI health check coordination (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension recall and titration audit (p5) | Hypertension patients with a recent blood pressure reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Breast screening recall audit (p7) | Breast screening coverage: aged 53 to 70 years old | — | PCN |
| Option 1 · Standardise annual asthma review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Structured hypertension and statin recall (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Pre-school MMR2 and booster recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target · Core20PLUS5 · 10YHP equity test | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
